<DOC>
	<DOCNO>NCT02725567</DOCNO>
	<brief_summary>The purpose study evaluate safety ivacaftor treatment , PK ivacaftor metabolites subject cystic fibrosis ( CF ) &lt; 24 month age treatment initiation CF transmembrane conductance regulator ( CFTR ) gene gate mutation</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics Ivacaftor Subjects With Cystic Fibrosis Who Are Less Than 24 Months Age Have CFTR Gating Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF sweat chloride value CF mutation criterion . Must 1 follow 9 CFTR mutation least 1 allele : G551D , G178R , S549N , S549R , G551S , G1244E , S1251N , S1255P , G1349D.G1349D . Weight &lt; 14 kg screen Day 1 Hematology , serum chemistry , coagulation , vital sign result screen clinically significant abnormality would interfere study assessment , judge investigator History illness condition , opinion investigator , might confound result study pose additional risk administer study drug subject Colonization organism associate rapid decline pulmonary status screen History abnormal liver function abnormal liver function screen History solid organ hematological transplantation Use moderate strong inducer inhibitor cytochrome P450 ( CYP ) 3A within 2 week Day 1 Participation clinical study involve administration either investigational marketed drug within 30 day 5 terminal halflives screen Hemoglobin ( Hgb ) &lt; 9.5 g/dL screen Chronic kidney disease Stage 3 Presence noncongenital progressive lens opacity cataract Screening</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>